Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Trimethoprim

Generic name
Trimethoprim
Brand name
ATC Code
J01EA01

Pharmacokinetics in children

The following kinetic parameters were found in 36 children aged 0-13 years:

 10 mg/kg one-time (n=18)
[Rylance]		3 mg/kg steady state twice daily (n=18)
[Hoppu]
Cmax 6 ±1.9 mg/l 2.2-2.3 µg/mL
Tmax 2.2 ± 1.2 hours 1.7-2.3 hours
t½ 6.8 ± 1.6 hours 3.7-5.4 hours
Vd 2.24 ± 0.57 l/kg 0.86-1.08 l/kg
Cl 0.241 ± 0.079 l/kg/hour 0.14-0.17 l/kg/hour

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Upper respiratory tract infection
  • Oral
    • 3 months up to 5 years
      • 6 - 9 mg/kg/day in 2 doses.
      • Duration of treatment:

        see treatment protocol. The duration of treatment can range from 7-10 days.

    • 3 months up to 5 years
      [5] [6]
      • 6 - 9 mg/kg/day in 2 doses.
      • Duration of treatment:

        see treatment protocol. The duration of treatment can range from 7-10 days.

    • 5 years up to 12 years
      [4]
      • 6 - 9 mg/kg/day in 1 - 2 doses.
      • Duration of treatment:

        see treatment protocol. The duration of treatment can range from 7-10 days.

    • 12 years up to 18 years
      [4]
      • 400 mg/day in 2 doses.
      • Duration of treatment:

        see treatment protocol. The duration of treatment can range from 7-10 days.
Maintenance treatment for chronic and prophylaxis for recurrent urinary tract infections, prophylaxis for vesicoureteral reflux (VUR), neurogenic bladder, bladder emptying disorders and urinary tract obstruction
  • Oral
    • 5 years up to 12 years
      • 50 mg/day in 1 dose
      • Directions for administration:

        Take in the evening

    • 12 years up to 18 years
      • 100 mg/day in 1 dose
      • Directions for administration:

        Take in the evening

    • < 5 years
      • 2 mg/kg/day in 1 dose. Max: 50 mg/day.
      • Directions for administration:

        Take in the evening

    • 5 years up to 12 years
      [4]
      • 50 mg/day in 1 dose
      • Directions for administration:

        Take in the evening

    • 12 years up to 18 years
      [4]
      • 100 mg/day in 1 dose
      • Directions for administration:

        Take in the evening

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

Adjustment in renal impairment as specified:

GFR 50-80 ml/min/1.73 m2
Adjustment not necessary
GFR 30-50 ml/min/1.73 m2
Adjustment not necessary
GFR 10-30 ml/min/1.73 m2
initially the standard dose for 3 days, then half dosage per administration. No interval lengthening.
GFR < 10 ml/min/1.73 m2
Not recommended to be used

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

The safety profile in children does not differ from the safety profile in adults. [SmPC]

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications in children

fragile X chromosome associated with mental retardation in children [SmPC]

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Intermediate-acting sulfonamides
J01EC02
Combinations of sulfonamides and trimethoprim, incl. derivatives
J01EE01
J01EE03

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. Hartwig NC, et al, Vademecum pediatrische antimicrobiële therapie, 2005
  2. Sandoz BV, SPC Trimethoprim (RVG 09001), www.cbg-meb.nl, Geraadpleegd 13 aug 2010, http://db.cbg-meb.nl/IB-teksten/h09001.pdf
  3. NVK, Richtlijn Urineweginfecties bij Kinderen, 09-06-2010
  4. Centrafarm BV, SmPC Trimethoprim (RVG 55722) 09-06-2016, www.geneesmiddeleninformatiebank.nl
  5. Hoppu K. , Age differences in trimethoprim pharmacokinetics: need for revised dosing in children? , Clin Pharmacol Ther, 1987, Mar;41(3), 336-43
  6. Rylance GW et al., Single dose pharmacokinetics of trimethoprim., Arch Dis Child., 1985, Jan;60(1), 29-3
  7. Lidefelt KJ et al., Single dose treatment of cystitis in children., Acta Paediatr Scand., 1991, Jun-Jul;80(6-7), 648-53
  8. Brendstrup L et al. , Nitrofurantoin versus trimethoprim prophylaxis in recurrent urinary tract infection in children. A randomized, double-blind study. , Acta Paediatr Scand, 1990, Dec;79(12), 1225-34
  9. Pinxteren, van B et al., NHG-Standaard Urineweginfecties (derde herziening)., Huisarts Wet, 2013, 56(6):, 270-80
  10. UpToDate®, Pediatric Drug information: Trimethoprim Lexicomp® Version 162.0, accessed 2018-08
  11. AVOXA, ABDA-Datenbank Interaktionen, accessed 08/2018
  12. AVOXA, ABDA-Datenbank Wirkstoffdossiers Trimethoprim, accessed 08/2018
  13. Infectopharm, SmPC Infectotrimet 50mg/5ml_100mg/ml Suspension zum Einnehmen (6613406.00.00_6613406.01.00), 12/2017
  14. Infectopharm, SmPC Infectotrimet 50mg/100mg/150mg/200mg Tabletten (6806051.01.00/6806051.02.00/6806051.03.00/6806051.00.00), 10/2016
  15. Infectopharm, SmPC Infectotrimet 50mg/5ml_100mg/ml Suspension zum Einnehmen (6613406.00.00_6613406.01.00), 12/2017
  16. Infectopharm, SmPC Infectotrimet 50mg/100mg/150mg/200mg Tabletten (6806051.01.00/6806051.02.00/6806051.03.00/6806051.00.00), 10/2016
  17. Brendstrup L et al., Nitrofurantoin versus trimethoprim prophylaxis in recurrent urinary tract infection in children. A randomized, double-blind study., Acta Paediatr Scand, 1990, Dec;79(12), 1225-34
  18. Hoppu K., Age differences in trimethoprim pharmacokinetics: need for revised dosing in children?, Clin Pharmacol Ther, 1987, Mar;41(3), 336-43

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes